Market Summary
USD34.49+0.81
Market Closed2.40%
HALO Stock Price
HALO RSI Chart
HALO Valuation
HALO Price/Sales (Trailing)
HALO Profitability
HALO Fundamentals
HALO Revenue
HALO Earnings
Price Action
52 Week Range
32.8359.46
(Low)(High)
Last 7 days
-4.4%
Last 30 days
-31.1%
Last 90 days
-40.0%
Trailing 12 Months
-10.9%
HALO Financial Health
HALO Investor Care
Peers (Alternatives to Halozyme Therapeutics)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
AMGN | 127.1B | 26.3B | 0.79% | 2.78% | 19.4 | 4.83 | 1.32% | 11.18% |
GILD | 99.8B | 27.3B | -4.19% | 39.66% | 21.72 | 3.66 | -0.09% | -26.23% |
MRNA | 58.1B | 19.3B | -4.61% | -16.03% | 6.95 | 3.02 | 4.29% | -31.47% |
BIIB | 39.0B | 10.2B | -0.92% | 26.77% | 12.8 | 3.83 | -7.36% | 95.80% |
| MID-CAP | ||||||||
NBIX | 9.4B | 1.5B | -5.59% | 3.19% | 60.62 | 6.29 | 31.34% | 72.43% |
DNLI | 3.1B | 108.5M | -21.66% | -32.82% | -9.55 | 28.71 | 122.90% | -12.19% |
BBIO | 2.2B | 107.9M | 21.83% | 38.60% | -4.63 | 20.79 | 54.84% | 17.36% |
BEAM | 2.2B | 60.9M | -25.55% | -48.21% | -7.49 | 35.56 | 17.51% | 22.00% |
| SMALL-CAP | ||||||||
RCUS | 1.3B | 112.0M | -7.70% | -49.25% | -4.81 | 11.47 | -70.76% | -603.77% |
REPL | 1.1B | 7.0M | -17.00% | 22.02% | -7.14 | 159.78 | 131.81% | -45.39% |
FATE | 524.4M | 96.3M | -14.58% | -86.07% | -1.86 | 5.45 | 72.44% | -32.79% |
NVAX | 519.7M | 2.0B | -33.63% | -92.58% | -0.79 | 0.26 | 72.89% | 62.27% |
SGMO | 276.9M | 111.3M | -42.96% | -71.96% | -1.44 | 2.49 | 0.54% | -7.86% |
VXRT | 101.6M | 107.0K | -17.23% | -85.52% | -0.94 | 949.93 | -88.00% | -52.91% |
IBIO | 26.0M | - | 40.00% | -84.44% | -0.32 | 3.21 | 0.51% | -185.61% |
Financials for Halozyme Therapeutics
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | 13.7% | 660 | 581 | 487 | 472 | 443 |
| S&GA Expenses | 20.1% | 144 | 120 | 98.00 | 53.00 | 50.00 |
| R&D Expenses | 23.0% | 67.00 | 54.00 | 46.00 | 39.00 | 36.00 |
| Costs and Expenses | 18.6% | 393 | 331 | 246 | 171 | 167 |
| EBITDA | 8.1% | 272 | 252 | 245 | 305 | - |
| EBITDA Margin | -5.0% | 0.41* | 0.43* | 0.50* | 0.65* | - |
| Earnings Before Taxes | 6.9% | 249 | 233 | 233 | 295 | 249 |
| EBT Margin | -6.0% | 0.38* | 0.40* | 0.48* | 0.63* | - |
| Interest Expenses | 17.4% | 17.00 | 14.00 | 9.00 | 7.00 | 8.00 |
| Net Income | -4.3% | 202 | 211 | 366 | 435 | 403 |
| Net Income Margin | -15.8% | 0.31* | 0.36* | 0.75* | 0.92* | - |
| Free Cahsflow | -0.9% | 235 | 238 | 290 | 287 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | -1.2% | 1,842 | 1,865 | 1,781 | 1,162 | 1,104 |
| Current Assets | 13.1% | 739 | 653 | 542 | 989 | 926 |
| Cash Equivalents | 59.1% | 234 | 147 | 91.00 | 118 | 119 |
| Inventory | -3.1% | 100 | 103 | 98.00 | 48.00 | 54.00 |
| Goodwill | 105.1% | 409 | 199 | 199 | - | - |
| Current Liabilities | 19.6% | 131 | 109 | 200 | 112 | 117 |
| Long Term Debt | 30.1% | 1,493 | 1,147 | 788 | 787 | - |
| LT Debt, Current | 0.1% | 13.00 | 13.00 | 99.00 | 90.00 | 89.00 |
| LT Debt, Non Current | 89.4% | 1,491 | 787 | - | - | - |
| Shareholder's Equity | 75.1% | 170 | 97.00 | 293 | 260 | 197 |
| Retained Earnings | 67.5% | 143 | 86.00 | 24.00 | 1.00 | -58.91 |
| Additional Paid-In Capital | 107.7% | 27.00 | 13.00 | 271 | 262 | 256 |
| Accumulated Depreciation | 9.7% | 15.00 | 14.00 | 13.00 | 13.00 | - |
| Shares Outstanding | 0.0% | 135 | 135 | 138 | 138 | 137 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | 0.0% | 240 | 240 | 292 | 289 | 299 |
| Share Based Compensation | 9.4% | 24.00 | 22.00 | 21.00 | 21.00 | 21.00 |
| Cashflow From Investing | 37.9% | -487 | -784 | -800 | -410 | -406 |
| Cashflow From Financing | 81.2% | 362 | 200 | 152 | -260 | 78.00 |
| Buy Backs | -25.0% | 200 | 267 | 86.00 | 151 | - |
Risks for HALO
What is the probability of a big loss on HALO?
78.8%
Probability that Halozyme Therapeutics stock will be more than 20% underwater in next one year
17.7%
Probability that Halozyme Therapeutics stock will be more than 30% underwater in next one year.
0.4%
Probability that Halozyme Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does HALO drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Halozyme Therapeutics was unfortunately bought at previous high price.
Drawdowns
Returns for HALO
Cumulative Returns on HALO
19.1%
10-Year Cumulative Returns
21.4%
7-Year Cumulative Returns
13.2%
5-Year Cumulative Returns
27.6%
3-Year Cumulative Returns
What are the long-term rolling returns for HALO?
FIve years rolling returns for Halozyme Therapeutics.
Annualized Returns
Which funds bought or sold HALO recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | added | 18.37 | 33,256,800 | 80,533,800 | 0.09% |
2023-03-10 | BAILLIE GIFFORD & CO | unchanged | - | 13,415 | 43,415 | -% |
2023-03-08 | SHEETS SMITH WEALTH MANAGEMENT | new | - | 259,805 | 259,805 | 0.04% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 228 | 1,476,000 | 1,871,000 | 0.01% |
2023-02-28 | Voya Investment Management LLC | reduced | -6.39 | 3,916,680 | 15,203,700 | 0.02% |
2023-02-24 | SRS Capital Advisors, Inc. | reduced | -18.42 | -236 | 1,764 | -% |
2023-02-24 | NATIXIS | sold off | -100 | -1,487,000 | - | -% |
2023-02-22 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | added | 9.97 | 602,000 | 1,633,000 | 0.02% |
2023-02-21 | NORTHWESTERN MUTUAL INVESTMENT MANAGEMENT COMPANY, LLC | reduced | -37.12 | -75,010 | 711,990 | 0.02% |
2023-02-21 | MACQUARIE GROUP LTD | added | 1.97 | 47,174,000 | 148,239,000 | 0.17% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Halozyme Therapeutics News
Schedule 13G FIlings of Halozyme Therapeutics
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 10, 2023 | invesco ltd. | 5.2% | 7,036,951 | SC 13G | |
| Feb 10, 2023 | blackrock inc. | 14.2% | 19,196,061 | SC 13G/A | |
| Feb 10, 2023 | artisan partners limited partnership | 5.3% | 7,140,953 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.84% | 13,303,847 | SC 13G/A | |
| Jan 26, 2023 | blackrock inc. | 13.6% | 18,214,071 | SC 13G/A | |
| Jan 20, 2023 | blackrock inc. | 13.6% | 18,214,071 | SC 13G | |
| Feb 04, 2022 | artisan partners limited partnership | 6.8% | 9,505,768 | SC 13G/A | |
| Jan 28, 2022 | blackrock inc. | 13.8% | 19,439,863 | SC 13G/A | |
| Feb 12, 2021 | bb biotech ag | 2.9% | 3,970,000 | SC 13G/A | |
| Feb 10, 2021 | artisan partners limited partnership | 7.6% | 10,284,136 | SC 13G/A |
HALO Fair Value
Halozyme Therapeutics fair value in different scenarios
The table shows the Fair Value estimates for Halozyme Therapeutics for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | 51.42 49.09% | 82.89 140.33% | 243.75 606.73% | 417.25 1109.77% | 617.69 1690.92% |
| Current Inflation | 47.09 36.53% | 74.47 115.92% | 212.88 517.22% | 358.73 940.10% | 526.84 1427.52% |
| Very High Inflation | 41.74 21.02% | 64.31 86.46% | 176.68 412.26% | 291.29 744.56% | 423.03 1126.53% |
Historical Halozyme Therapeutics Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of Halozyme Therapeutics
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 24, 2023 | ARS | ARS | |
| Mar 24, 2023 | DEF 14A | DEF 14A | |
| Mar 24, 2023 | DEFA14A | DEFA14A | |
| Mar 16, 2023 | 8-K | Current Report | |
| Mar 13, 2023 | 8-K | Current Report | |
| Mar 09, 2023 | 4 | Insider Trading | |
| Mar 01, 2023 | 4 | Insider Trading | |
| Mar 01, 2023 | 4 | Insider Trading | |
| Feb 28, 2023 | 4 | Insider Trading | |
| Feb 23, 2023 | 8-K | Current Report |
Latest Insider Trading transactions for HALO
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-09 | Torley Helen | sold | -427,270 | 42.727 | -10,000 | president and ceo |
2023-03-09 | Torley Helen | acquired | 146,600 | 14.66 | 10,000 | president and ceo |
2023-03-08 | Torley Helen | sold | -432,590 | 43.259 | -10,000 | president and ceo |
2023-03-08 | Torley Helen | acquired | 146,600 | 14.66 | 10,000 | president and ceo |
2023-03-07 | Torley Helen | acquired | 146,600 | 14.66 | 10,000 | president and ceo |
2023-03-07 | Torley Helen | sold | -454,690 | 45.469 | -10,000 | president and ceo |
2023-03-01 | Torley Helen | gifted | - | - | -10,000 | president and ceo |
2023-03-01 | Henderson Jeffrey William | sold | -477,100 | 47.71 | -10,000 | - |
2023-02-28 | Henderson Jeffrey William | sold | -485,100 | 48.51 | -10,000 | - |
2023-02-27 | LaBarre Michael J. | sold | -495,483 | 49.5483 | -10,000 | svp, chief technical officer |
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
HALO Income Statement
2022-12-31Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| Revenues: | |||
| Total revenues | $ 660,116 | $ 443,310 | $ 267,594 |
| Operating expenses: | |||
| Cost of sales | 139,304 | 81,413 | 43,367 |
| Amortization of intangible assets | 43,148 | 0 | 0 |
| Research and development | 66,607 | 35,672 | 34,236 |
| Selling, general and administrative | 143,526 | 50,323 | 45,736 |
| Total operating expenses | 392,585 | 167,408 | 123,339 |
| Operating income | 267,531 | 275,902 | 144,255 |
| Other income (expense): | |||
| Investment and other income, net | 1,046 | 1,102 | 5,425 |
| Induced conversion expense related to convertible notes | (2,712) | (20,960) | 0 |
| Interest expense | (16,947) | (7,526) | (20,378) |
| Net income before income taxes | 248,918 | 248,518 | 129,302 |
| Income tax expense (benefit) | 46,789 | (154,192) | 217 |
| Net income | $ 202,129 | $ 402,710 | $ 129,085 |
| Net income per share: | |||
| Basic (USD per share) | $ 1.48 | $ 2.86 | $ 0.95 |
| Diluted (USD per share) | $ 1.44 | $ 2.74 | $ 0.91 |
| Shares used in computing net income per share: | |||
| Basic (shares) | 136,844 | 140,646 | 136,206 |
| Diluted (shares) | 140,608 | 146,796 | 141,463 |
| Royalties | |||
| Revenues: | |||
| Total revenues | $ 360,475 | $ 203,900 | $ 88,596 |
| Product sales, net | |||
| Revenues: | |||
| Total revenues | 191,030 | 104,224 | 55,987 |
| Revenues under collaborative agreements | |||
| Revenues: | |||
| Total revenues | $ 108,611 | $ 135,186 | $ 123,011 |
HALO Balance Sheet
2022-12-31Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 234,195 | $ 118,719 |
| Marketable securities, available-for-sale | 128,599 | 622,203 |
| Accounts receivable, net and other contract assets | 231,072 | 90,975 |
| Inventories | 100,123 | 53,908 |
| Prepaid expenses and other current assets | 45,024 | 40,482 |
| Total current assets | 739,013 | 926,287 |
| Property and equipment, net | 75,570 | 8,794 |
| Prepaid expenses and other assets | 26,301 | 13,414 |
| Goodwill | 409,049 | 0 |
| Intangible assets, net | 546,652 | 0 |
| Deferred tax assets, net | 44,426 | 155,434 |
| Restricted cash | 500 | 500 |
| Total assets | 1,841,511 | 1,104,429 |
| Current liabilities: | ||
| Accounts payable | 17,693 | 1,541 |
| Accrued expenses | 96,516 | 24,441 |
| Deferred revenue, current portion | 3,246 | 1,746 |
| Current portion of long-term debt, net | 13,334 | 89,419 |
| Total current liabilities | 130,789 | 117,147 |
| Deferred revenue, net of current portion | 2,253 | 2,530 |
| Long-term debt, net | 1,492,766 | 787,255 |
| Long-term debt, net | 30,433 | 544 |
| Contingent liability | 15,472 | 0 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity: | ||
| Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding | 0 | 0 |
| Common stock - $0.001 par value; 300,000 shares authorized; 135,154 and 137,498 shares issued and outstanding at December 31, 2022 and 2021, respectively | 135 | 138 |
| Additional paid-in capital | 27,368 | 256,347 |
| Accumulated other comprehensive loss | (922) | (620) |
| Retained earnings (Accumulated deficit) | 143,217 | (58,912) |
| Total stockholders’ equity | 169,798 | 196,953 |
| Total liabilities and stockholders’ equity | $ 1,841,511 | $ 1,104,429 |